Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.88
27.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Net Income (Common)
Kiniksa Pharmaceuticals Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
Net Income (Common)
-$9.1m
|
CAGR 3-Years
63%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
Kiniksa Pharmaceuticals Ltd
Glance View
Founded with a vision to tackle some of the most challenging inflammatory and autoimmune diseases, Kiniksa Pharmaceuticals Ltd. emerged as a nimble player in the competitive biotechnology landscape. This company, leveraging the vast potential of advanced scientific knowledge and biotechnological breakthroughs, focuses on developing and commercializing innovative therapies. Its portfolio is strategically designed to address unmet needs in the treatment of debilitating diseases. Central to its operations is a robust pipeline of monoclonal antibodies and cutting-edge biologics that promise new hope for patients. Guided by a commitment to rigorous clinical development and strategic collaborations, Kiniksa seeks to navigate the complexities of regulatory pathways, bringing its specialized therapeutic solutions to global markets. The financial engine of Kiniksa's ambitious journey is fueled by a combination of strategic partnerships, successful licensing agreements, and prudent capital allocation. By forging alliances with larger pharmaceutical firms, the company gains access to invaluable resources and distribution channels while minimizing its financial risks. This collaborative approach not only expedites the development process but also amplifies market reach, ensuring that novel treatments are accessible to the patients who need them. Revenue streams are bolstered through a mix of upfront payments, milestone achievements, and royalties as its therapies progress through stages of clinical trials and, finally, into the hands of healthcare providers. This business model, one that intertwines innovation with strategic alliances, is designed to sustain growth, balance risk, and ultimately fulfill the company's mission of transforming patients’ lives.
See Also
What is Kiniksa Pharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
-9.1m
USD
Based on the financial report for Sep 30, 2024, Kiniksa Pharmaceuticals Ltd's Net Income (Common) amounts to -9.1m USD.
What is Kiniksa Pharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
45%
Over the last year, the Net Income (Common) growth was -35%. The average annual Net Income (Common) growth rates for Kiniksa Pharmaceuticals Ltd have been 63% over the past three years , 45% over the past five years .
You don't have any saved screeners yet
